Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
boston top stories
life sciences
national blog main
clinical trials
deals
national top stories
san francisco blog main
abbvie
allergan
ally bridge group
alzheimer's disease
azacitidine
beta-thalassemia
big data analytics
blackrock
casdin capital
crispr
cynthia collins
dacogen
decitabine
diabetic nephropathy
dna
editas medicine
epigenetics
epizyme
eventide asset management
farydak
flagship pioneering
focal segmental glomerulosclerosis
fulcrum therapeutics
gene editing
goldfinch bio
insulated genomic domains
irving investors
jay ghosh
kaleido biosciences
leber congenital amaurosis type 10
What
biotech
3
×
medicines
3
×
genetic
new
research
abbvie
aims
alliance
analysis
approach
based
bio
bring
called
company
debuts
develop
developing
diseases
drug
drugs
editas
editing
employing
epigenetic
epigenetics
exits
experimental
field
flagship’s
gene
goldfinch
ipo
kidney
later
lead
million
morning
omega
pact
Language
unset
Current search:
biotech
×
medicines
×
boston
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further